Kangtai Biological and AstraZeneca terminate cooperation on adenovirus vector COVID-19 vaccine
October 3, 2025
Source: drugdu
141
On September 30, Kangtai Biological(300601) issued an announcement that the company signed a license termination agreement with AstraZeneca UK Limited (AstraZeneca) to terminate the cooperation in the research and development, production and commercialization of ChAdOx1 adenovirus vector new crown vaccine.
The termination of the cooperation on the licensed product and the signing of the termination agreement are prudent decisions made by the company after comprehensive assessment of factors such as the prevalent strains of the new coronavirus vaccine and the significant changes in the market environment, as well as its own resource allocation.
The company mentioned that in the future it will concentrate its superior resources to focus on the research and development and industrialization of multi-component and multivalent vaccines, adult vaccines, innovative vaccines, and therapeutic vaccines, continue to deepen its roots in the vaccine field, and enhance its core competitiveness.
By mid-2025, CanSino Biologics achieved revenue of 1.392 billion yuan and net profit attributable to shareholders of the parent company of 37.53 million yuan.
Source: https://finance.eastmoney.com/a/202509303527468080.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
